From: Novel germline MSH2 mutation in lynch syndrome patient surviving multiple cancers
Site of tumor | Age at diagnosis (years) | Histology | Stage (TNM) | Treatment |
---|---|---|---|---|
Ovary (right) | 38 | Mucinous cystadenocarcinoma | I (T1N0M0) | Radical hysterectomy+chemotherapy+ radiotherapy (1986) |
Rectosigmoid | 47 | Mucinous adenocarcinoma | III (T3N1M0) | Resection of rectosigmoid part with "end-to-end anastomosis"+ chemotherapy |
Breast (left) | 51 | Ductal adenocarcinoma | II (T2N0M0) | Mastectomy + radiotherapy (4 fields), tamoxifen (20 mg) 3 years |
Ureter (left) | 56 | Transitional cell ureter carcinoma (G2) | II (T2N0M0) | Resection of ureter + nephroectomy |
Adenoma of parathyroid | 57 | Â | Â | Ultrasound biopsy |
Ureteral metastasis in liver (S5-6) | 60 | Transitional cell ureter carcinoma (G2) | IV | Radiofrequency ablation |
Colon (ascending) | 61 | Adenocarcinoma with partial mucinous differentiation (G2) | II (T3N0M0) | Right hemicolectomy |